4564.T OncoTherapy Science JPX 29 Jan 2026 earnings ahead: clinical readout may move stock
We see 4564.T stock trading at JPY 21.00 intraday on the JPX as OncoTherapy Science prepares an earnings update around its clinical program. Volume today is 28,911,900.00 shares while the 50-day average is 21.24 JPY. The earnings release on 30 Jan 2026 will spotlight Phase III S-588410 progress and near-term funding needs. Investors should watch clinical milestones and cash-per-share metrics that could drive short-term moves.
4564.T stock quick snapshot and intraday picture
On 29 Jan 2026 intraday 4564.T stock trades between JPY 21.00 and JPY 22.00. Market cap stands at JPY 7,216,515,054.00 with year range JPY 19.00 to JPY 35.00.
Average daily volume is 52,649,850.00 shares. Key trailing metrics include EPS -2.83 and PE -7.42, reflecting ongoing research costs and negative earnings.
Earnings spotlight: what to expect on 30 Jan 2026
The company lists an earnings announcement for 30 Jan 2026. We expect commentary on trial enrollment, milestone timing, and R&D spend. Management guidance will be key because R&D drives more than 53.91% of revenue.
Analysts will parse cash-per-share and operating burn. With cash per share JPY 5.26, capital runway comments could swing the stock intraday.
Pipeline and clinical drivers for 4564.T stock
OncoTherapy Science’s pipeline includes S-588410 in Phase III for esophageal cancer. Success there would materially change revenue prospects and valuation multiples for 4564.T stock.
Other assets include OTS167, OTS964 and antibody programs. Clinical readouts are binary events and can produce wide intraday moves in biotech names on JPX.
Valuation, balance sheet and risks in 4564.T analysis
The stock shows a price-to-sales ratio of 7.54 and price-to-book of 4.06, which are rich versus healthcare peers. The current ratio is 8.63, indicating strong short-term liquidity.
Primary risks include trial failure, dilution from equity raises, and sustained negative margins. Recent financial growth shows revenue up 22.93% year over year, which contrasts with negative EPS.
Meyka AI grade and model forecast for 4564.T stock
Meyka AI rates 4564.T with a score out of 100: 65.62, Grade B, Suggestion HOLD. This grade factors in S&P 500 and sector comparisons, sector performance, financial growth, key metrics, forecasts, analyst consensus, and fundamentals.
Meyka AI’s forecast model projects a yearly price of JPY 18.22, implying -13.24% versus the current JPY 21.00. The monthly model shows JPY 28.51, implying +35.76%. Forecasts are model-based projections and not guarantees. These grades and forecasts are informational only and not financial advice.
Technicals and intraday trading signals for 4564.T stock
Momentum indicators are near overbought. RSI sits at 68.81 and MACD histogram is positive at 0.40. Bollinger upper band is JPY 23.10.
Traders should watch ATR JPY 1.54 for stop placement. With average volume higher than today, intraday liquidity can spike on news. We view short-term technicals as mixed-to-cautiously bullish ahead of the earnings release.
Final Thoughts
Key takeaways for 4564.T stock on 29 Jan 2026: the market is focused on the upcoming earnings and clinical-readout commentary. The stock price is JPY 21.00 with heavy historical volume and wide year range. Valuation metrics like P/S 7.54 and P/B 4.06 make the equity expensive versus typical healthcare averages, but the balance sheet shows current ratio 8.63 and cash per share JPY 5.26. Meyka AI’s forecast model projects a yearly target of JPY 18.22, implying -13.24% downside versus today. For traders, watch intraday volume, management commentary, and trial milestones on 30 Jan 2026. We note that forecasts are model-based projections and not guarantees. Meyka AI, an AI-powered market analysis platform, provides this data-driven view to guide risk-aware decisions.
FAQs
When is OncoTherapy Science reporting earnings?
OncoTherapy Science has an earnings announcement scheduled for 30 Jan 2026. Expect management comments on trial progress, R&D spend, and cash runway that could drive intraday moves in 4564.T stock.
What are the biggest drivers for 4564.T stock price?
Clinical readouts, especially Phase III S-588410 news, and capital raises. Also watch revenue trends, cash-per-share, and any guidance tied to R&D and milestone income.
What is Meyka AI’s short-term forecast for 4564.T stock?
Meyka AI’s monthly model gives JPY 28.51, a +35.76% upside. The yearly projection is JPY 18.22, a -13.24% downside. These are model-based projections and not guarantees.
How risky is investing in 4564.T stock?
Biotech risk is high due to binary trial outcomes and dilution risk. OncoTherapy shows strong liquidity but negative EPS. Investors should weigh clinical risk versus balance-sheet strength.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
